Working... Menu

A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01353664
Recruitment Status : Completed
First Posted : May 16, 2011
Results First Posted : December 19, 2013
Last Update Posted : April 19, 2016
Information provided by (Responsible Party):
Celgene Corporation

Brief Summary:
This study is intended to provide access to Romidepsin for participants who received Romidepsin in other trials sponsored by Gloucester Pharmaceuticals or Celgene Corporation and for participants whom the investigator feels may benefit from continuing treatment with Romidepsin.

Condition or disease Intervention/treatment Phase
Lymphoma Cancer Drug: Romidepsin Phase 2

Detailed Description:
Participants must have previously participated in a Romidepsin study sponsored by Gloucester Pharmaceuticals or Celgene Corporation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols
Study Start Date : May 2011
Actual Primary Completion Date : September 2012
Actual Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Romidepsin

Arm Intervention/treatment
Experimental: Romidepsin
This study is an open-label, single-arm study. The study is divided into the Screening Period, Treatment Period, and Follow-up Period.
Drug: Romidepsin
The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.
Other Name: Istodax®, ROMI

Primary Outcome Measures :
  1. Summary of Participants With Treatment Emergent Adverse Events (TEAEs) [ Time Frame: All AEs were recorded by the Investigator from the time the participant signed the informed consent to 28 days after the last dose of study drug; maximum drug exposure was 231 days ]
    An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. Adverse events were assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4: On the following is the scale: Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe and Undesirable AE, Grade 4 = Life-threatening or Disabling AE, and Grade 5 = Death. Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention. A TEAE is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Previously participated in and fulfilled the inclusion and exclusion criteria in one of the romidepsin clinical trials: ROMI-ADVM-001 (NCT01324310), ROMI-ADVM-002 (NCT01324323). Additional studies added at the discretion of the medical monitor of the study
  2. Physician believes continued romidepsin treatment is of benefit to participant.
  3. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
  4. Able to adhere to the study visit schedule and other protocol requirements.
  5. Negative urine or serum pregnancy test for females of child bearing potential; and
  6. All females of child bearing potential must use an effective method of contraception (an intrauterine contraceptive device [IUCD] or double contraceptive method using condoms and a diaphragm plus spermicide) during the treatment period and for at least 1 month thereafter. Male participants should use contraception during the treatment period and for at least 3 months thereafter. Female participants should avoid the use of estrogen-containing contraceptives, since romidepsin may reduce the effectiveness of estrogen-containing contraceptives. An in vitro binding assay determined that romidepsin competes with β-estradiol for binding to estrogen receptors.

Exclusion Criteria

  1. Concomitant use of drugs that may cause a significant prolongation of the corrected measurement of the time between the start of cardiac Q wave and the end of the T wave (QTc) .
  2. Concomitant use of Cytochrome P 450 3A4 (CYP3A4) strong inhibitors within 1 week of trial medications.
  3. Concomitant use of therapeutic warfarin due to a potential drug interaction. Use of a low dose of warfarin or another anticoagulant to maintain patency of venous access port and cannulas is permitted.
  4. Prior chemotherapy or radiotherapy or any investigational agent after the last dose of romidepsin from the preceding romidepsin study.
  5. Participants who are pregnant or breast-feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01353664

Layout table for location information
United States, Florida
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
United States, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
United Kingdom
Sarah Cannon Research UK
London, United Kingdom, W1G6AD
Sponsors and Collaborators
Celgene Corporation
Layout table for investigator information
Study Director: Ken Takeshita, MD Celgene Corporation

Layout table for additonal information
Responsible Party: Celgene Corporation Identifier: NCT01353664     History of Changes
Other Study ID Numbers: ROMI-ADVM-004
2010-023040-32 ( EudraCT Number )
First Posted: May 16, 2011    Key Record Dates
Results First Posted: December 19, 2013
Last Update Posted: April 19, 2016
Last Verified: April 2016

Keywords provided by Celgene Corporation:
rollover protocol
Gloucester Pharmaceuticals
Celgene Corporation
continuing treatment

Additional relevant MeSH terms:
Layout table for MeSH terms
Antibiotics, Antineoplastic
Antineoplastic Agents